Supplementary Figure 1: Guideline conformity to the Stupp regimen in patients with newly diagnosed glioblastoma multiforme in China
figureposted on 2021-09-14, 10:49 authored by Yu Wang, Jianmin Zhang, Wenbin Li, Taipeng Jiang, Songtao Qi, Zhongping Chen, Jingbo Kang, Lei Huo, Yunjie Wang, Qichuan Zhuge, Guodong Gao, Yuping Wu, Hua Feng, Gang Zhao, Xiaopeng Yang, Hui Zhao, Yirong Wang, Hui Yang, Dezhi Kang, Jun Su, Liang Li, Chuanlu Jiang, Gang Li, Yongming Qiu, Weimin Wang, Handong Wang, Zaihua Xu, Liwei Zhang, Renzhi Wang
Supplementary Figure 1 - Flowchart of patient recruitment procedures.
Aims: To determine how consistently Chinese glioblastoma multiforme (GBM) patients were treated according to the Stupp regimen.
Patients and methods: The proportion of treatments conforming to the Stupp regimen and reasons for non-conformity were evaluated in 202 newly diagnosed GBM patients.
Results: Only 15.8% GBM patients received treatments compliant with the Stupp regimen. Main deviations were temozolomide dosages >75 mg/m2 (58/120, 48.3%) and treatment durations <42 days (84/120, 70.0%) in the concomitant and temozolomide dosages <150 mg/m2 (89/101, 88.1%) in the maintenance phase. Median OS (27.09 vs 18.21 months) and PFS (14.27 vs 12.10 months) times were longer in patients who received Stupp regimen compliant treatments.
Conclusion: Increased conformity to the Stupp regimen is needed for GBM patients in China.